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ABSTRACT
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell 
precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed 
a screening for JAK2 mutations and translocations, analyzed the clinical outcome and 
studied the efficacy of two JAK inhibitors in primary BCP-ALL cells. Importantly, we 
identify a number of limitations of JAK inhibitor therapy.
JAK2 mutations mainly occurred in the poor prognostic subtypes BCR-ABL1-like 
and non- BCR-ABL1-like B-other (negative for sentinel cytogenetic lesions). JAK2 
translocations were restricted to BCR-ABL1-like cases. Momelotinib and ruxolitinib 
were cytotoxic in both JAK2 translocated and JAK2 mutated cells, although efficacy 
in JAK2 mutated cells highly depended on cytokine receptor activation by TSLP. 
However, our data also suggest that the effect of JAK inhibition may be compromised 
by mutations in alternative survival pathways and microenvironment-induced 
resistance. Furthermore, inhibitors induced accumulation of phosphorylated JAK2Y1007, 
which resulted in a profound re-activation of JAK2 signaling upon release of the 
inhibitors. This preclinical evidence implies that further optimization and evaluation 
of JAK inhibitor treatment is necessary prior to its clinical integration in pediatric 
BCP-ALL.
INTRODUCTION
Janus kinase 2 (JAK2) is a member of the non-
receptor tyrosine kinase family and mediates intracellular 
signaling upon activation of cytokine receptors, which 
lack an intrinsic tyrosine kinase domain, such as cytokine 
receptor-like factor 2 (CRLF2). Ligand binding (e.g. TSLP 
for CLRF2) induces dimerization of cytokine receptors 
chains, resulting in activation of JAK proteins via cross-
phosphorylation. JAKs activate signal transducers of 
transcription (STATs), which, upon dimerization, migrate 
to the nucleus and induce transcription of genes involved 
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in differentiation and proliferation of hematopoietic cells 
[1].
JAK2 has seven homologous domains (JH1-JH7). 
The JH1 and JH2 domains are C-terminally located and 
comprise the catalytic kinase (JH1) and pseudokinase 
(JH2) domain. The JH2 domain has a dual regulatory 
function: exerting a negative regulatory effect on the 
kinase domain, and facilitating JAK2 activation upon 
receptor activation by ligand binding [2]. The JH3-JH4 
domains share homology with Src homology 2 (SH2) 
domains and mediate protein-protein interactions. The 
N-terminal located JH6 and JH7 domains, also known as 
the FERM domain, are required for binding of JAK2 to 
cytokine receptors [1].
In pediatric BCP-ALL patients, gain of function 
mutations and translocations affecting JAK2 have been 
identified [3–16]. Genomic translocations of JAK2 have 
been observed in high-risk BCR-ABL1-like patients. For 
several of these fusion genes, constitutive JAK2 kinase 
activation has been demonstrated [12-14, 17]. Point 
mutations often occur in Down Syndrome ALL, mainly 
affect exon 16 (located in the pseudokinase domain), and 
functionally cooperate with overexpression of the type I 
cytokine receptor CRLF2 [6, 9, 10]. Indeed, requirement 
for the interaction of mutant JAK2 with a cytokine receptor 
was shown in cell lines models by several groups [6, 8, 9].
Mutations and translocations represent biologically 
distinct entities, but both are potential targets for precision 
medicines. JAK inhibitors were shown to be effective 
against mutant and translocated JAK2 in vitro [3, 5, 7, 
8, 12, 13, 17, 18]. However, in vivo mouse studies show 
conflicting data and none has been reported to be curative 
[13, 18–22]. To date, clinical data with JAK inhibitors 
are scarce. The Children’s Oncology Group performed 
a phase 1 dosing study of the JAK inhibitor ruxolitinib, 
but no cases harboring JAK2 activating mutations or 
translocations were included [23].
Several papers have reported data with a focus on 
either fusion genes or mutations of JAK2, although often 
with small sample size or only in specific subtypes of 
BCP-ALL. Furthermore, most reports lack ex vivo efficacy 
data of JAK inhibitors in primary leukemic cells. To assess 
the clinical potential of JAK inhibitors in pediatric BCP-
ALL, we performed a comprehensive study to determine 
the frequency and prognosis of JAK2 mutations and 
translocations among different subtypes of childhood 
BCP-ALL. Furthermore, the biological efficacy of the 
JAK inhibitors momelotinib and ruxolitinib was studied 
in primary leukemic cells harboring JAK2 aberrations, and 
the clonal stability of JAK2 mutations was investigated 
in ALL patient derived xenograft models. We show that 
JAK inhibitors are overall effective towards BCP-ALL 
cells, but also identified a number of limitations of JAK 
inhibitor therapy.
RESULTS
Frequency and type of JAK2 aberrations in 
BCP-ALL patients
JAK2 mutation status was analyzed in 461 newly 
diagnosed BCP-ALL cases representing all major subtypes 
seen in children, with a distribution that is comparable to 
the general pediatric BCP-ALL population. JAK2 exons 
16, 20, 21 and 23 were examined by targeted amplicon 
sequencing at a median read depth of 673, 577, 711 and 
944, respectively. Analyses revealed that 3.5% (16/461) 
of these BCP-ALL cases harbored JAK2 mutations, 
which were detected in 7.6% (6/79) of BCR-ABL1-like 
cases, 11.9% (8/67) of non-BCR-ABL1-like B-other 
cases, and 1.6% (2/124) of high hyperdiploid cases. No 
JAK2 mutations were detected in KMT2A-AFF1 (0/15), 
BCR-ABL1 (0/26), ETV6-RUNX1 (0/124) or TCF3-PBX1 
(0/26) cases. The variant allele frequency (VAF) ranged 
from 1.0% to 56% (Figure 1A). Seven patients carried two 
different JAK2 mutations, and one patient even harbored 
three different JAK2 mutations. Mutations involved amino 
acid residue R683 in 13 of 16 mutated cases, which is 
an important amino acid for the JH2 domain mediated 
negative auto-regulation of JAK2 activity [24]. CRLF2 
overexpression was detected in 87.5% (14/16) of these 
cases (Figure 1A, Supplementary Figure 1). One CRLF2 
low expressing case harbored a subclonal JAK2 mutation, 
suggesting that CRLF2 overexpression might be subclonal 
as well. The other case harbored a JAK2R923H with a VAF of 
50%, suggesting that this mutation in the kinase domain is 
not associated with CRLF2 overexpression.
The screen for JAK2 fusion genes was confined 
to 153 BCP-ALL cases, negative for sentinel BCP-
ALL associated lesions (KMT2A-rearranged, BCR-
ABL1, ETV6-RUNX1, TCF-PBX1, high hyperdiploid), 
as JAK2 translocations were previously reported in this 
group of patients [12, 13, 25]. No JAK2 translocations 
were detected in 76 non-BCR-ABL1-like B-other cases, 
whereas in five of the 77 (6.5%) BCR-ABL1-like cases 
JAK2 tyrosine kinase activating fusion genes were 
identified. The cases involved three PAX5-JAK2 cases, 
one BCR-JAK2 case and one TERF2-JAK2 case (Figure 
1A). The PAX5-JAK2 and BCR-JAK2 fusions contained 
identical exons as reported before [12, 13]. The TERF2-
JAK2 case displayed an in frame fusion of TERF2 exon 
10 to JAK2 exon 19. All JAK2 fusion genes harbored an 
intact JH1 kinase domain (Supplementary Figure 2). Gene 
expression data revealed high expression levels of JAK2 
in these cases (Supplementary Figure 3). Absence of the 
cytokine receptor-binding FERM domain in JAK2 fusion 
protein suggests that they signal independent of a cytokine 
receptor.
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Clinical characteristics and prognosis of patients 
harboring JAK2 lesions
Ten out of sixteen (62.5%) JAK2-mutated patients 
remained in continuous complete remission at more than 
5 years of follow up. The median time to relapse in the 
six other patients was 2.1 years [range 0.71-7.8 years]. 
Minimal residual disease (MRD) data were available for 
nine patients. The four patients with high MRD levels 
(≥10-3) at day 29/33 of treatment (time point 1 of COALL 
and DCOG protocol, respectively) relapsed, whereas the 
remaining five mutated patients with low MRD levels 
remained in continuous complete remission (p=0.008, 
Fisher exact test).
Figure 1: JAK2 aberrations in BCP-ALL patients.  (A) Type of lesions, clinical characteristics and follow-up of JAK2 lesion 
positive patients. Treatment protocol and risk group assigned to each patient per protocol have been listed (HR-S: High Risk Standard. 
HR: High Risk. MR: Median Risk. SR: Standard Risk. LR-S: Low Risk Standard. LR-R: Low Risk Reduced. NHR: Non-High Risk). 
WBC indicates white blood cell count. Minimal residual disease (MRD) levels at day 29/33 of treatment of COALL and DCOG protocol, 
respectively. Type of translocation or mutation is listed. VAF indicates the variant allele frequency (%). CRLF2 status indicates gene 
expression below (low) or above (high) the 90th percentile levels. Right panel: Bar plot represents years from diagnosis to event or last 
contact. In blue: cases in complete clinical remission. In red: cases with an event (relapse or death). (B) Cumulative incidence of relapse 
curves for patients with JAK2 lesions (green line), JAK2 wildtype BCR-ABL1-like and B-other cases (grey line), and JAK2 wildtype 
remaining BCP-ALL cases (black line; ETV6-RUNX1, high hyperdiploid, TCF3-PBX1). Patients were treated according to ALL8, ALL9, 
ALL10, COALL97 or COALL03 protocol. Cumulative incidence of relapse (CIR) was estimated using a competing risk model. Relapse 
and non-response were considered as event, and death as competing event. Non-response was counted as event at day 79. The Gray’s test 
was applied to test for equality of CIRs (JAK2 lesion versus remaining BCP-ALL p=0.04; JAK2 wildtype B-other/BCR-ABL1-like versus 
remaining BCP-ALL p=0.04).
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Three out of the five cases harboring JAK2 fusion 
genes remained in continuous complete remission at more 
than 5 years of follow up, whereas two cases suffered from 
a relapse within 2.4 years of diagnosis (Figure 1A). Both 
patients who relapsed were assigned to the High Risk arm 
of the COALL-03 study protocol because of unfavorable 
age (>10 years) or high white blood cell count at diagnosis 
(>50 WBC/nl).
Cumulative incidence of relapse in these JAK2 
aberrant patients did not differ from JAK2 wildtype 
BCR-ABL1-like and B-other cases. Both displayed an 
unfavorable outcome compared to remaining BCP-ALL 
cases (p=0.04; Figure 1B). These findings underline 
the clinical relevance of JAK2 lesions. Mutations and 
translocations represent biologically distinct entities, but 
both may be targetable by JAK-inhibitors.
Leukemic cells with JAK2 lesions can be 
targeted by JAK inhibitors
Primary leukemic and patient-derived-xenograft 
(PDX) cells (Supplementary Figure 4, [26]) were exposed 
to momelotinib and ruxolitinib. JAK2 translocated cells 
were more sensitive to both momelotinib and ruxolitinib 
compared to JAK2 wildtype cases (P<0.05; Figure 2A and 
2B, Supplementary Figure 5. JAK2 mutated cells were 
less sensitive to these inhibitors than JAK2 fusion positive 
cells, and were only marginally more sensitive than 
wildtype cells (P<0.05). Leukemic cells without genetic 
JAK2 aberrations were resistant to ruxolitinib, but showed 
some sensitivity to momelotinib. Importantly, normal bone 
marrow mononuclear cells were resistant to both inhibitors 
(Supplementary Figure 5). Both JAK inhibitors effectively 
reduced levels of phosphorylated STAT5Y694 and/or 
STAT1Y701 (Figure 2C and 2E, Supplementary Figure 6).
The marginal sensitivity for both inhibitors and the 
low levels of phosphorylated STAT5 in JAK2 mutated 
cells may be explained by lack of human TSLP ligand to 
activate the CRLF2 pathway in our culture conditions. 
Addition of human TSLP sensitized JAK2 mutated cells 
to ruxolitinib, but not to momelotinib (P<0.01, Figure 3A 
and 3B, Supplementary Figures 7 and 8). TSLP exposure 
did not change the efficacy of JAK inhibitors in JAK2-
fusion positive cells, confirming cytokine-independent 
signaling (Figure 3C and 3D, Supplementary Figure 
7). JAK2 wildtype leukemic cells were not sensitized 
to JAK inhibitors by TSLP treatment (Figure 3E and 3F, 
Supplementary Figure 7). In the presence of TSLP both 
JAK2 translocated and JAK2 mutated cells were sensitive 
to JAK inhibitors (Figure 3G and 3H). At the protein level, 
TSLP exposure upregulated the levels of phosphorylated 
STAT1Y701 and STAT5Y694 in JAK2R683S mutated cells, 
whereas no effect was observed in JAK2 fusion positive and 
JAK2 wildtype leukemic cells (Figure 3I-3K, Supplementary 
Figure 9). Notably, TSLP triggered the phosphorylation and 
hence activation of the MEK/ERK pathway in JAK2R683S 
mutated cells, but not in JAK2R683G mutated cells (Figure 3I 
and 3L), suggesting that this activation is context-dependent. 
Phosphorylation of STAT1Y701 and STAT5Y694 was inhibited 
by momelotinib and ruxolitinib (Figure 3L).
JAK2 inhibition results in accumulation of 
phosphorylated JAK2
Exposure of primary leukemic cells, harboring 
TERF2-JAK2 or PAX5-JAK2 translocations, to 
momelotinib and ruxolitinib resulted in accumulation of 
phosphorylated JAK2Y1007 fusion proteins (Figure 2C and 
2D). Wash out of both inhibitors induced a slight rebound 
effect with upregulation of pSTAT1Y701 and pSTAT5Y694 in 
TERF2-JAK2 cells (Figure 4A, Supplementary Figure 10). 
This rebound effect was also observed in the JAK2V617F-
positive leukemic cell line HEL (Supplementary Figures 
11 and 12). Phosphorylated JAK2Y1007 accumulated upon 
exposure to ruxolitinib. Removal of the inhibitor resulted 
in reactivation of JAK2 signaling, observed by a clear 
increase in phosphorylated STAT5Y694 levels within 4 
hours (time point 100 hours; Supplementary Figure 11A 
and 11B). The inhibitory effect of momelotinib was 
more transient compared to ruxolitinib, resulting in an 
earlier reactivation of JAK2, observed by high levels of 
phosphorylated STAT5Y694 after 48 hours of momelotinib 
exposure (Supplementary Figure 11A).
Mesenchymal stromal cells protect against JAK 
inhibitors
Leukemic cells reside in the bone marrow 
microenvironment, where they disrupt normal 
hematopoietic stem cell niches [27]. This abnormal 
niche protects ALL cells against chemotherapy [28, 29]. 
To study whether the bone marrow microenvironment 
protects against JAK inhibitors, we mimicked this niche by 
co-culturing PDX cells with bone marrow mesenchymal 
stromal cells (MSCs) derived from a leukemia patient. 
Survival of leukemic cells was improved in co-cultures 
together with MSCs compared to leukemic cells cultured 
without MSCs (Figure 5A). In these PDX/MSC co-
cultures, JAK inhibitors decreased leukemic cell survival 
(Supplementary Figure 13A-13G). However, leukemic 
cells were more resistant to ruxolitinib in PDX/MSC co-
culture compared to culture without MSCs (P<0.05). A 
similar trend was observed for momelotinib (Figure 5B 
and 5C, Supplementary Figure 13H and 13I).
Different outgrowth pattern in xenografts
The outgrowth patterns of primary leukemic cells 
(>90% blast purity) in three NSG mice per patient was 
determined by paired-end deep-sequencing of JAK2 
hot spot regions (exon 16, 20, 21 and 23; median read 
depth 554, 465, 411 and 593, respectively). PDX cells 
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originating from a JAK2R863G mutated case had a different 
VAF profile compared to the original patient sample 
(Figure 6A, Supplementary Figure 14A). The primary 
sample contained a major JAK2R683G clone at a VAF of 
63% and a minor KRASG12D clone at VAF 14%. In two out 
of three PDX samples generated, the VAF of the JAK2R683G 
mutation increased to 98% (PDX1) and 99% (PDX3), 
whereas in the remaining PDX sample the VAF decreased 
to 49% (PDX2). In contrast, the KRASG12D mutation 
increased to a VAF 23% in this PDX2 sample, whereas 
this mutation was not detected in PDX1 and PDX3. The 
reduced VAF of the JAK2 clone in PDX2 did not result 
in a decreased efficacy of momelotinib or ruxolitinib 
(Figure 6B). However, levels of pMEK1/2S217/221 and 
pERK1/2T202/204 in this sample were increased compared 
to the other two PDX samples (Figure 6C). Exposure 
to both JAK inhibitors did not decrease the levels of 
phosphorylated MEK and ERK.
Sanger sequencing of JAK2R683S and JAK2R683T PDX 
models also indicated a change in the VAF of PDX cells 
compared to the primary sample. In PDX cells from three 
NSG mice injected with JAK2R683S cells, the A/T peak 
ratio at nucleotide position 2049 differed, suggesting 
heterogeneity in frequency of JAK2 mutations between 
samples (Supplementary Figure 14B). Strikingly, two mice 
injected with JAK2R683T mutated leukemic cells developed 
JAK2 wildtype leukemia (Supplementary Figure 14C). 
Although the JAK2 mutation was lost, CRLF2 expression 
levels remained high (Supplementary Figure 14D and 14E). 
TSLP stimulation activated the JAK2 pathway signaling 
(Supplementary Figure 14F), but cells were not sensitive 
for JAK2 inhibition (Supplementary Figure 14G and 14H).
DISCUSSION
This study aimed to evaluate the clinical need 
(frequency of lesions and prognostic value) and potential 
of JAK inhibitors in pediatric BCP-ALL. For this purpose 
pediatric BCP-ALL patients were screened for JAK2 
lesions. JAK2 point mutations were found in 3.6% of our 
BCP-ALL patients, of which the majority were JAK2R683 
mutations. These mutations were solely detected in BCR-
ABL1-like, B-other and high hyperdiploid patients, but not 
in KMT2A-AFF1, BCR-ABL1, ETV6-RUNX1 or TCF3-
Figure 2: The efficacy of JAK inhibitors on JAK2 translocated and mutated cells.  (A-B) Leukemic (PDX or primary patient) 
cells were incubated for four days with to an increasing concentration range of momelotinib or ruxolitinib, after which cell viability was 
measured using an MTT assay. Sensitivity of exposed cells was calculated relative to vehicle treated controls. Individual samples were 
tested in duplicate. Mean±SEM of JAK2 translocated cases (n=5), JAK2 mutated cases (n=6) and JAK2 wildtype cases (n=4) is shown. Cell 
viability of samples was compared using independent sample T-test. **p≤0.01, *p≤0.05, 1JAK2 translocations versus JAK2 wildtype,2JAK2 
translocations versus JAK2 mutations,3JAK2 mutations versus JAK2 wildtype. (C-E) TERF2-JAK2, PAX5-JAK2 and JAK2R683G PDX cells 
were exposed for four hours to vehicle control medium, 1.5 μM momelotinib or 0.75 μM ruxolitinib, after which (phosphorylated) TERF2-
JAK2, JAK2, STAT1 and STAT5 levels were analyzed using western blot (25 μg lysate).
Oncotarget89928www.impactjournals.com/oncotarget
Figure 3: The effect of TSLP stimulation on the efficacy of JAK inhibitors.  Cells (PDX or primary ALL) were pre-incubated 
for 1 hour with or without 25 ng/ml TSLP, after which cells were exposed for four days to indicated concentrations of momelotinib or 
ruxolitinib. Cell viability was measured using an MTT assay. Sensitivity was calculated relative to vehicle treated controls. Individual 
samples were tested in duplicate. (A-B) Efficacy of momelotinib and ruxolitinib on JAK2 mutated cells with or without TSLP pre-
incubation. Mean±SEM of six independent samples is shown. (C-D) Efficacy of momelotinib and ruxolitinib on cells with JAK2 
translocations. Mean±SEM of two independent samples is shown. (E-F) Efficacy of momelotinib and ruxolitinib on JAK2 wildtype PDX 
cells. Mean±SEM of three independent samples is shown. (G-H) Combined graph of the efficacy of momelotinib (G) and ruxolitinib (H) 
on TSLP stimulated cells with JAK2 mutations (n=6), JAK2 translocations (n=2), or JAK2 wildtype cells (n=3). Mean±SEM of independent 
samples is shown. Cell viability of samples was compared using the independent sample T-test. **p≤0.01, *p≤0.05. 1JAK2 translocations 
versus JAK2 wildtype,2JAK2 wildtype versus JAK2 mutations. (I-K) Western blot of JAK2R683S, TERF2-JAK2 and JAK2wt PDX cells with 
or without TSLP stimulation (25 ng/ml for 1 hour). (L) JAK2R683G cells were pre-incubated for 1 hour with or without 25 ng/ml TSLP, after 
which cells were exposed for four hours to vehicle control medium, 1.5 μM momelotinib or 0.75 μM ruxolitinib. Levels of (phosphorylated) 
JAK2, STAT1, STAT5, MEK1/2 and ERK1/2 were analyzed using western blot.
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PBX1 patients. JAK2 translocations were detected in the 
poor prognostic BCR-ABL1-like group, but not in non-
BCR-ABL1-like B-other cases. The prognosis of patients 
with JAK2 aberrations was as poor as JAK2 wildtype 
BCR-ABL1-like and non-BCR-ABL1-like B-other patients.
JAK2 mutations were not detected as frequently 
in our DCOG/COALL sequencing cohort as reported 
for COG high-risk cohorts [5, 10]. Two independent 
classifiers are used to describe BCR-ABL1-like BCP-
ALL [30–32]. Differences in genetic ancestry between 
the American COG and European DCOG/COALL 
cohorts likely affected the signatures to classify patients 
as BCR-ABL1-like. Hence, genetic differences, or more 
specifically the lack of Hispanic/Latino cases [10, 33], 
might explain the lower frequencies of JAK2 mutations, 
as well as the difference in treatment outcome.
Figure 4: Accumulation of pJAK2Y1007 results in a rebound effect of JAK2.  TERF2-JAK2 PDX cells were incubated for four 
hours with or without 1.5 μM momelotinib or 0.75 μM ruxolitinib, after which cells were washed to remove the JAK inhibitors. Half of the 
cells were exposed for another 1.5 hours to 1.5 μM momelotinib or 0.75 μM ruxolitinib, whereas the other cells were incubated in vehicle 
control (Ctr) medium. Protein expression levels were examined by western blot (25 μg lysate).
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A targeted approach was used to detect JAK2 
translocations. All cases with high JAK2 expression 
levels harbored one of the known fusion genes, making 
it therefore unlikely that novel fusion genes were missed.
The poor outcome of cases harboring JAK2 lesions 
underline the clinical relevance of activated JAK2. The 
therapeutic potential of JAK2 was demonstrated by 
efficacy of JAK inhibitors in JAK2 mutated and JAK2 
translocated primary BCP-ALL cells. JAK2 translocated 
cells were sensitive to both JAK inhibitors, independent 
of cytokine activation. In contrast, the efficacy of JAK 
inhibitors in JAK2 mutated cells highly depended on 
CRLF2 activation by TSLP, which is in concordance 
with previous reports [3, 5, 7, 8, 18]. These results 
highlight the importance of TSLP in in vitro and in vivo 
studies involving JAK2 mutations. Since human CRLF2 
cannot be activated by mouse TSLP, conventional mouse 
xenograft models are not suitable to test the efficacy of 
ruxolitinib and other JAK inhibitors on JAK2 mutated 
cells. Absence of human TSLP in ALL xenograft mouse 
models might therefore explain the disappointing efficacy 
of JAK inhibitors in in vivo models [19–22]. The recently 
engineered xenograft model which synthesizes human 
TSLP may overcome this limitation [34].
Despite the need for human TSLP, we and others 
observed engraftment of primary JAK2 mutated cells 
in NSG mice, giving rise to leukemia within months 
after intra-femoral injection [19, 20, 22]. This implies 
that the proliferation of JAK2 mutated leukemic cells 
in the mouse bone marrow does not (solely) depend on 
CRLF2 signaling, but may be supported by activation of 
alternative pathways [35, 36]. This argues against targeted 
monotherapy, as cells might escape via an alternative 
pathway, such as the RAS pathway [36, 37]. This is 
Figure 5: Efficacy of JAK inhibitors in co-culture.  The response of CD19+ PDX cells, co-cultured with MSCs (hCD19-), to 
increasing concentrations of momelotinib and ruxolitinib, was assessed after four days of culture using flow cytometry. Cells were stained 
with Brilliant Violet 421 anti-human CD19 antibody, FITC Annexin V, and PI. Viability was calculated relative to vehicle controls. (A) 
Survival of PDX cells in mono-culture, or PDX/MSC co-culture. Individual samples were tested in duplicate. Bars represent the mean±SEM 
of two BCR-JAK2, two TERF2-JAK2, one PAX5-JAK2, three JAK2R683G and two JAK2wt samples. Cell viability of samples in mono-culture 
versus co-culture was compared using the independent sample T-test. *p≤0.05. (B-C) The effect of 1.5 μM and 3.0 μM momelotinib or 
ruxolitinib on the viability of PDX cells with JAK2 translocations in mono-culture, or in co-culture with primary MSCs. Mean±SEM of 
three JAK2 translocated samples is shown. Cell viability of samples was compared using independent sample T-test. *p≤0.05.
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further strengthened by a study in Down syndrome ALL, 
in which a switch was observed from a JAK2 mutation at 
initial diagnosis to a RAS-mutation at relapse [38]. In the 
current study, we also observed co-occurrence of JAK2 
and KRAS lesions in non-Down syndrome BCP-ALL 
cells. More importantly, these JAK2 and KRAS mutations 
showed different outgrowth patterns in NSG xenograft 
models. Co-occurrence of these mutations suggests that 
a combination of JAK and RAS pathway inhibitors may 
be more effective for JAK2-aberrant cases. Moreover our 
results indicate that JAK2 mutations by itself might not be 
drivers of leukemic outgrowth, which is also corroborated 
by the outgrowth of JAK2 wildtype leukemic cells in mice 
injected with JAK2R683T cells. Taken together, these data 
imply that 1) the expansion properties of JAK2 mutated 
leukemic cells vary, 2) other subclones (e.g. KRASG12D) can 
grow out at the expense of the major JAK2 mutated clone, 
3) JAK2 mutations can get lost while leukemia progresses. 
Therefore, JAK2 mutations are most likely secondary 
lesions, in contrast to JAK2 translocation, which are 
primary lesions. The selection of alternative pathways 
indicates a potential risk for use of JAK inhibitors in 
JAK2 mutated cases without detailed monitoring of the 
mutational status of leukemic cells in time.
Interestingly, we observed a difference in the 
cytotoxicity of momelotinib and ruxolitinib. Both agents 
fully inhibited JAK/STAT signaling by downregulation of 
phosphorylation levels of STAT1 and STAT5. However, 
only momelotinib affected JAK2 wildtype and non-TSLP 
stimulated JAK2 mutated cells, regardless of activation 
Figure 6: Outgrowth pattern of JAK2 mutated samples in xenografts.  (A) VAF of JAK2R683G and KRASG12D in primary leukemic 
cells and three PDX samples of the same patient was determined using targeted amplicon sequencing. (B) PDX cells were pre-incubated 
for 1 hour with 25 ng/ml TSLP, after which they were exposed for four days to indicated concentrations of momelotinib or ruxolitinib in 
the presence of TSLP. Cell viability was measured using an MTT assay. Cell survival was calculated relative to vehicle treated controls. 
Samples were tested in duplicate. Mean±SD of each sample is shown. (C) Protein expression levels of PDX samples, exposed to 1.5 μM 
momelotinib or 0.75 μM ruxolitinib for four hours.
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of STAT5. Therefore, it is likely that momelotinib also 
affects alternative targets [39, 40]. In addition, our data 
revealed that exposure to JAK inhibitors, especially 
ruxolitinib, resulted into accumulation of phosphorylated 
JAK2Y1007, which consequently induced a profound re-
activation of downstream STAT signaling. Accumulation 
of phosphorylated JAK2Y1007 is in concordance with 
other reports [21, 41–43]. The rebound effect observed 
in the present study identifies an important limitation of 
these agents. As type I inhibitors bind JAK2 in its active 
conformation, reactivation of JAK2 may be overcome 
by type II inhibitors, which bind JAK2 in its inactive 
conformation [18, 44]. Preclinical in vitro and in vivo data 
indicate high efficacy of the type II inhibitor CHZ868. 
Clinical data of this inhibitor and other novel inhibitors 
are warranted.
Besides studying the mechanism of action, we 
showed influences of the bone marrow microenvironment 
on the efficacy of JAK inhibitors. Microenvironment-
induced resistance of leukemic cells has been reported for 
conventional drugs, e.g. prednisolone and asparaginase, 
for imatinib in BCR-ABL1-positive cells, and for JAK 
inhibitors in the present study [45–49]. These data imply 
that the local tumor environment can stimulate a survival 
program, which may provide leukemic cells a way to 
escape from JAK inhibitors.
Taken together, JAK2 lesions are infrequently 
found in children with newly diagnosed BCP-ALL and 
are mainly restricted to BCR-ABL1-like and non-BCR-
ABL1-like B-other cases (negative for sentinel cytogenetic 
lesions). Although mutations and translocations represent 
biologically distinct entities, both may be targetable 
by JAK inhibitors. Indeed, we showed efficacy of 
momelotinib and ruxolitinib in both cell types. As both 
momelotinib and ruxolitinib have a short half-life (less 
than half a day), the observed rebound effect may be 
therapeutically of risk [50, 51]. Although it should be 
confirmed by functional in vivo studies, our data suggest 
that the effect of JAK inhibition may be compromised 
by microenvironment-induced resistance and induction 
of alternative survival pathways. In conclusion, JAK 
inhibitors may be considered to be added to, but not 
substitute, chemotherapy for patients with JAK2 
aberrations, especially for those at high risk of relapse due 
to high MRD levels upon induction therapy. Therapeutic 
monitoring for activation of alternative pathways (e.g. 
RAS) is highly recommended.
MATERIALS AND METHODS
Primary patient-derived material
Bone marrow and/or peripheral blood samples were 
obtained from children (1-18 years) with newly diagnosed 
ALL. Written informed consent was obtained from parents 
or guardians to use excess diagnostic material for research 
purposes, as approved by the institutional review board. 
These studies were conducted in accordance with the 
Declaration of Helsinki. Mononuclear cells were isolated 
and processed as described previously [52]. Samples 
were enriched towards > 90% leukemic cells by depletion 
of non-leukemic cells using immunomagnetic beads. 
The major cytogenetic subtypes were determined using 
fluorescent in situ hybridization, (RT-) PCR, and the 
110-probeset gene expression classifier [31]. Patients were 
treated according to the DCOG ALL8, ALL9 or ALL10 
protocol, or the COALL-06-97 and COALL-07-03 study 
protocols [53–57]. Patient characteristics were provided 
by the central study centers of DCOG (The Hague, the 
Netherlands) and COALL (Hamburg, Germany).
Mesenchymal stromal cells (MSCs) were isolated 
from the bone marrow aspirate of a BCR-ABL1-like 
patient as described previously [58]. Purity of MSCs 
was assessed by negativity for the hematopoietic 
markers CD34, CD45, and CD19, and positivity for the 
mesenchymal markers CD13, CD29, CD44, CD54, CD73, 
CD90, CD105, CD146 and CD166, as detected by flow 
cytometry (MACS Quant). Expression was measured 
using the human mesenchymal stem cell marker antibody 
panel (R&D Systems, Minneapolis, Minnesota, USA), and 
CD13-APC, CD29-APC, CD34-PE, CD54-PE, CD73-
PE, IgG1-PE, and IgG1-APC (BD Biosciences, San Jose, 
California, USA).
Cell lines
The human erythroleukemia cell line HEL was 
obtained from the German Collection of Microorganisms 
and Cell lines (DSMZ, Braunschweig, Germany) and 
cultured in RPMI-1640 medium, supplemented with 10% 
fetal calf serum (Bodinco BV, Alkmaar, Netherlands), 
100 units/ml penicillin, 100 μg/ml streptomycin and 
0.125 μg/mL fungizone (Life Technologies, Bleiswijk, 
Netherlands). The identity of the cell line was routinely 
verified by DNA fingerprinting. Additionally, presence of 
Mycoplasma was excluded every 25 passages by PCR.
Patient-derived-xenograft cells
Primary leukemic cells were transplanted by 
intra-femoral injection in 7-12 weeks old female NOD.
Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (Charles River, 
Wilmington, Massachusetts, USA; three NSG mice per 
patient), as approved by the animal ethics committee 
(EMC 2863). Mice were sacrificed upon overt leukemia 
or 6 months after injection. Leukemic cells were isolated 
from bone marrow and spleen. The percentage of human 
leukemic cells was analyzed by flow cytometry (APC anti-
human CD19, PE anti-human CD45 and FITC anti-mouse 
CD45; Biolegend, London, UK) and May-Grünwald-
Giemsa staining. Patient-derived-xenograft cells (PDX) 
were enriched for > 90% human leukemic cells using anti-
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human-CD19 immunomagnetic beads (MACS Miltenyi, 
Leiden, Netherlands).
JAK2 mutations
JAK2 mutations status was analyzed in 461 BCP-
ALL cases, representing the major cytogenetic subtypes 
(6% BCR-ABL1, 17% BCR-ABL1-like, 15% non-BCR-
ABL1-like B-other, 27% ETV6-RUNX1, 27% high 
hyperdiploid, 3% KMT2A-AFF1, 6% TCF3-PBX1). 
Genomic DNA was isolated using Trizol reagent (Life 
Technologies), or in some cases using the DNeasy blood 
and tissue kit (Qiagen) according to manufacturer’s 
instructions, and quantified using the Qubit dsDNA Broad 
Range Assay Kit (Life Technologies). 100-250 ng genomic 
DNA was used to prepare sequencing libraries according 
to manufacturer’s instructions. Successful library 
preparation, correct amplicon length and concentration 
were assessed using the Labchip GX genomic analyzer 
(Caliper Life Sciences Benelux N.V.) with the HT DNA 
12K Reagent Kit, Version 2. Samples were pooled equi-
molarly and sequenced on an Illumina MiSeq in paired-
end reads of 250bp each. The custom amplicons covered 
the exons 16, 20, 21 and 23 and represent the mutational 
hotspot region of JAK2.
Sequence reads were exported in fastq format and, 
aligned to the standard 1000 genomes human reference 
sequences (version b37, from the GATK resource bundle 
provided by the Broad institute, USA), using BWA 
version 0.7.10 and the GATK indel realigner version 3.3-
0. Freebayes version 0.9.18-24, Varscan version 2.3.7, 
Bcftools version 1.0, and GATK version 3.3-0 were used 
to call single nucleotide variants. The resulting variant 
call format files were annotated using snpEff and snpSift 
version 4.1a and the dbNSFP version 2.7 database. Variants 
were combined and filtered based on several criteria using 
an in-house developed pipeline: variants were excluded if 
they were not located in targeted regions, were reported by 
only one caller, had coverage of < 100 reads, or had < 10 
reads supporting the variant allele. Furthermore, variants 
had to occur at least once with a VAF above 2% in any 
sample and to be distributed equally between runs according 
to a chi-square test. Additionally only variants were taken 
into account if they were reported in the COSMIC V73 
GRCh37 database, lead to an amino acid change, were 
unlikely to be a germline variant and not a known SNP. 
SNPs were defined as having a mean population frequency 
of ≥ 5% across the 1000Gp1 complete human population, 
1000Gp1 population of European decent, and the ESP-6500 
population of European decent allele frequency databases. 
Variants found in ≥ 10 samples with a mean and median 
VAF > 40% were labelled as possible germline. Sufficient 
coverage was crucial to detect subclonal mutations, which 
could be reliably detected ≥ 5% VAF in on average 91% 
of the cases. Detection of variants with a frequency of 1% 
was limited to a smaller group (26%), and is therefore a 
conservative estimate in the present study.
Genomic DNA of PDX cells was used to identify 
JAK2 mutations in exon 16. Samples were analyzed by 
Baseclear B.V. using Sanger sequencing (forward primer 
5’-ATGCCTCCAAATTATTATACTATCA-3’, reverse 
primer 5’-ATCACCTCACAGTCCATGGTTAT-3’).
JAK2 translocations
Presence of ten recurrently reported JAK2 
translocations was examined by RT-PCR in 153 BCP-
ALL cases, negative for sentinel BCP-ALL associated 
lesions (n=77 BCR-ABL1-like, n=76 non-BCR-ABL1-like 
B-other). Total RNA was extracted from leukemic cells 
using Trizol reagents (Life Technologies). cDNA was 
synthesized using random hexamers and oligodT primers, 
and M-MLV reverse transcriptase (Promega, Leiden, 
Netherlands). RT-PCR was performed in a final volume of 
25 μl, containing 0.3 μM forward primer, 0.3 μM reverse 
primer, 200 μM dNTPs, 1x PCR buffer II, 4 mM MgCl2, 
0.125 μl AmpliTaq DNA polymerase (Promega) and 2.5 
μl cDNA. Primer sequences are shown in Supplementary 
Table 1. PCR products were Sanger sequenced by 
Baseclear B.V. (Leiden, Netherlands).
CRLF2 status
CRLF2 expression levels were determined by 
Affymetrix gene expression microarrays (U133 Plus 2.0; 
Santa Clara, California, USA), of a previously published 
cohort of pediatric BCP-ALL patients at initial diagnosis 
[59]. High CRLF2 expression levels are indicative P2RY8-
CRLF2 and IGH-CRLF2 translocations in different 
studies, though not all cases with high CRLF2 mRNA 
expression levels harbor CRLF2 rearrangements [10, 16, 
59–61]. Of 406 cases, both CRLF2 gene expression data 
and JAK2 mutation status was available. Signal intensity 
of probeset 208303_s_at above the 90th percentile levels 
was classified as CRLF2 high, as described previously 
[59].
In addition, CRLF2 expression in primary 
leukemic and PDX samples was determined using RT-
qPCR and SYBR green. CRLF2 expression (forward 
primer 5’-ACGGGGATCTCCTCTATG-3’, reverse 
primer: 5’-GAGGCGTTGG TGTCTCT-3’) was 
calculated relative to RSP20 expression (forward primer 
5’-AAGGGCTGAGGATTTT TG-3’, reverse primer 
5’-CGTTGCGGCTTGTTAG-3’), using the comparative 
cycle time (Ct) method; 2-DCt x 100%, whereby DCt 
= CtCRLF2 – CTRPS20. RT-qPCR expression values were 
correlated to Affymetrix microarray data of probeset 
208303_s_at.
JAK2 expression levels
JAK2 expression levels were analyzed using 
Affymetrix gene expression microarrays, in a previously 
published pediatric BCP-ALL cohort [59]. Signal intensity 
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of probeset 205841_at was used to quantify JAK2 gene 
expression.
Ex vivo drug cytotoxicity assays
Cell-intrinsic resistance towards momelotinib and 
ruxolitinib (Selleck Chemicals, Kirby Drive, Houston, 
USA) was evaluated as described previously [52]. Briefly, 
leukemic cells were exposed to a concentration range 
(24μM to 750 nM) of these compounds for four days and 
cytotoxicity was quantified using 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT). For TSLP 
stimulation, cells were pre-incubated for 1 hour with 25 
ng/ml TSLP (R&D systems, Oxon, UK). In addition to 
single cell cultures, leukemic cells (1*106 cells) were co-
cultured with primary MSCs (5*104 cells) for four days 
in a 24 well plate in the presence of a dilution series of 
momelotinib and ruxolitinib. Cell survival was quantified 
using flow cytometry (MACSQuant, FlowJo 10.0.8r1), 
and cells were stained with Brilliant Violet 421 anti-
human CD19 antibody (Biolegend), FITC Annexin 
V (Biolegend), and Propidium Iodide (PI; Invitrogen, 
Bleiswijk, Netherlands), as described previously [45].
Western blotting
Leukemic cells were lysed in lysis buffer 
supplemented with freshly added protease and 
phosphatase inhibitors. 25μg (BCA method; Thermo 
Scientific) lysate was loaded on 10% mini protean precast 
gels (BioRad, Veenendaal, Netherlands), and transferred 
to a nitrocellulose membrane (Biorad). Primary antibody 
incubation was performed according to manufacturer’s 
protocol. Anti-JAK2 (#3230), anti-phospho-JAK2-
Tyr1007 (#4406), anti-phospho-STAT5-Tyr694 (#9351), 
anti-phospho-STAT1-Tyr701 (#9167), anti-Stat1 (#9175), 
anti-phospho-MEK1/2-Ser217/221 (#9154), anti-MEK1/2 
(#4694), anti-phospho-Erk1/2-T202/204 (#4370), anti-
Erk1/2 (#91078), and anti-αTubulin (#2144) were obtained 
from Cell Signaling Technology (Danvers, Massachusetts, 
USA). Anti-β-actin (ab6276) was obtained from Abcam 
(Cambridge, UK), and anti-STAT5 (sc-835) from Santa 
Cruz (Heidelberg, Germany). Blots were stained with 
secondary antibodies (IRDye 680RD- or 800CW-labelled 
anti-rabbit and IRDye 680RD- or 800CW-labelled anti-
mouse; Li-Cor Biosciences, Leusden, Netherlands) and 
scanned using the Odyssey infrared imaging system 
(Li-Cor Biosciences). To reprobe membranes, they were 
stripped in NewBlot Nitrocellulose stripping buffer (Li-
Cor Biosciences) according to manufacturer’s protocol. 
BCR-JAK2, PAX5-JAK2 and TERF2-JAK2 proteins were 
separated from wildtype JAK2 based on size (~94, 57, 95 
and 125 kDa, respectively).
Statistics
Cumulative incidence of relapse (CIR) was 
estimated using a competing risk model. Relapse and non-
response (counted at day 79) were considered as event, 
and death as competing event. The Gray’s test was applied 
to test for equality of CIRs [62]. Outcome analyses were 
performed in R 3.0.1, using the packages cmprsk version 
2.2-7 [63], mstate version 0.2.7 [64], and survival version 
2.37-4 [65].
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